These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29515243)

  • 1. Reply to Lambros et al.
    Tang Z; Zhang J; Chen H; Lu S; Cheng J; Tang G; Medeiros LJ
    Mod Pathol; 2018 Mar; 31(3):541-542. PubMed ID: 29515243
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al.
    Pietrantonio F; Cremolini C
    Ann Oncol; 2015 Nov; 26(11):2353. PubMed ID: 26347099
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of Response to manuscript entitled 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14(1-2): 51-69).
    Paz-Ares L; Moecks J; Klughammer B
    J Cell Mol Med; 2011 May; 15(5):1225. PubMed ID: 21362132
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.
    Beau-Faller M; Cadranel J
    Ann Oncol; 2016 Feb; 27(2):359-60. PubMed ID: 26658890
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to the letter to the editor 'KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC' by Robles et al.
    Lee SY; Choi JE; Park JY
    Ann Oncol; 2016 Feb; 27(2):361-3. PubMed ID: 26578724
    [No Abstract]   [Full Text] [Related]  

  • 6. p53 mutations, benzo[a]pyrene and lung cancer: a reply.
    Pfeifer GP; Denissenko MF; Tang M
    Mutagenesis; 1998 Nov; 13(6):537-8. PubMed ID: 9862184
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to the letter to the editor 'ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer' by Uguen et al.
    Ilie M; Hofman P
    Ann Oncol; 2015 Aug; 26(8):1802. PubMed ID: 25957328
    [No Abstract]   [Full Text] [Related]  

  • 8. Correspondence re: Feyler et al., Point: Myeloperoxidase (-463)G --> a polymorphism and lung cancer risk. Cancer Epidemiol. Biomark. Prev., 11: 1550-1554, 2002, and Xu et al., Counterpoint: The myeloperoxidase (-463)G --> a polymorphism does not decrease lung cancer susceptibility in Caucasians. 11: 1555-1559, 2002.
    Dally H; Bartsch H; Risch A
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):683. PubMed ID: 12869414
    [No Abstract]   [Full Text] [Related]  

  • 9. MET DNA Alterations in NSCLC-Reply.
    Tong JH; Chan AW; To KF
    Clin Cancer Res; 2016 Jul; 22(14):3699. PubMed ID: 27422203
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to the letter to the editor of Lambros et al.
    Sterlacci W; Tzankov A; Savic S
    Virchows Arch; 2017 Nov; 471(5):687-688. PubMed ID: 28879608
    [No Abstract]   [Full Text] [Related]  

  • 11. In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.
    Park S; Lee SH; Park K
    J Thorac Oncol; 2019 Dec; 14(12):e279-e280. PubMed ID: 31757381
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis'
(Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69).
    Watkins C; Rukazenkov Y
    J Cell Mol Med; 2010 Nov; 14(11):2693-4. PubMed ID: 21029366
    [No Abstract]   [Full Text] [Related]  

  • 13. A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer".
    van Veggel B; de Langen AJ
    Lung Cancer; 2020 Oct; 148():181. PubMed ID: 32800358
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Kitajima S; Barbie DA
    Clin Cancer Res; 2018 Mar; 24(6):1243-1245. PubMed ID: 29343556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutations in sarcomatoid and large cell carcinoma of the lung-reply.
    Yvorel V; Forest F; Karpathiou G; Péoc'h M
    Hum Pathol; 2017 May; 63():220-221. PubMed ID: 27939780
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to v.R. Bhatt et Al and m.C. Chamberlain.
    Welsh JW; McGovern SL; Wefel JS; Komaki R; Brown PD; Soh HE
    J Clin Oncol; 2013 Sep; 31(25):3165-6. PubMed ID: 23943829
    [No Abstract]   [Full Text] [Related]  

  • 17. Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer.
    Devarakonda S; Govindan R; Morgensztern D
    Cancer Cell; 2020 Sep; 38(3):320-322. PubMed ID: 32857949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to: "Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously".
    Saleh MM; Scheffler M; Merkelbach-Bruse S; Wolf J; Buettner R
    J Thorac Oncol; 2022 Jun; 17(6):e57-e59. PubMed ID: 35623679
    [No Abstract]   [Full Text] [Related]  

  • 19. Human lung adenocarcinoma cells with an EGFR mutation are sensitive to non-autophagic cell death induced by zinc oxide and aluminium-doped zinc oxide nanoparticles.
    Bai KJ; Chuang KJ; Ma CM; Chang TY; Chuang HC
    J Toxicol Sci; 2017; 42(4):437-444. PubMed ID: 28717102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?
    Ma PC
    Clin Cancer Res; 2019 Apr; 25(8):2375-2378. PubMed ID: 30770350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.